[EN] BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE [FR] COMPOSÉS BENZIMIDAZOLE ET AZABENZIMIDAZOLE QUI INHIBENT LA KINASE DES LYMPHOMES ANAPLASIQUES
[EN] BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE [FR] COMPOSÉS BENZIMIDAZOLE ET AZABENZIMIDAZOLE QUI INHIBENT LA KINASE DES LYMPHOMES ANAPLASIQUES
BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE
申请人:Boezio Christiane M.
公开号:US20130217668A1
公开(公告)日:2013-08-22
Compounds of Formula (I) are useful inhibitors of anaplastic lymphoma kinase. Compounds of Formula (I) have the following structure: where the definitions of the variables are provided herein.
Benzimidazole and azabenzimidazole compounds that inhibit anaplastic lymphoma kinase
申请人:Boezio Christiane M.
公开号:US09115127B2
公开(公告)日:2015-08-25
Compounds of Formula (I) are useful inhibitors of anaplastic lymphoma kinase. Compounds of Formula (I) have the following structure: where the definitions of the variables are provided herein.
(IFIs), though severe toxicity derived from self-aggregation greatly limits its clinical application. Herein, we applied a bisamidation strategy at the C16-COOH and C3′-NH2 to improve the therapeutic properties by suppressing self-aggregation. It was found that basic amino groups at the residue of C16 amide were beneficial to activity, while lipophilic fragments contributed to toxicity reduction. Additionally